Trimethoprim, Sulfamethoxazole Drug Combination

SAN DIEGO — Trimethoprim sulfamethoxazole prophylaxis halves serious infection risk in patients with granulomatosis with polyangiitis receiving B-cell depletion with rituximab, according to data presented at ACR Convergence 2023.

A 7-day course of ciprofloxacin or trimethoprim/sulfamethoxazole for presumed, symptomatic UTI in afebrile men was noninferior to 14 days of treatment, a randomized trial showed.

Patients with systemic lupus erythematosus, especially those who are positive for anti-Sm antibodies, are at greater risk for adverse events associated with trimethoprim-sulfamethoxazole, according to data presented at the ACR Convergence 2020 virtual meeting.